- Home
- MDAI vs PMN Comparison
MDAI vs PMN Comparison
Compare MDAI & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- PMN
- Stock Information
- Founded
- MDAI 2013
- PMN 2004
- Country
- MDAI United States
- PMN Canada
- Employees
- MDAI N/A
- PMN N/A
- Industry
- MDAI Medical/Dental Instruments
- PMN Pharmaceuticals and Biotechnology
- Sector
- MDAI Health Care
- PMN Health Care
- Exchange
- MDAI Nasdaq
- PMN Nasdaq
- Market Cap
- MDAI 28.3M
- PMN 33.7M
- IPO Year
- MDAI N/A
- PMN N/A
- Fundamental
- Price
- MDAI $2.06
- PMN $0.93
- Analyst Decision
- MDAI Strong Buy
- PMN
- Analyst Count
- MDAI 3
- PMN 0
- Target Price
- MDAI $4.50
- PMN N/A
- AVG Volume (30 Days)
- MDAI 1.8M
- PMN 49.6K
- Earning Date
- MDAI 11-06-2024
- PMN 11-14-2024
- Dividend Yield
- MDAI N/A
- PMN N/A
- EPS Growth
- MDAI N/A
- PMN N/A
- EPS
- MDAI N/A
- PMN N/A
- Revenue
- MDAI $27,264,000.00
- PMN N/A
- Revenue This Year
- MDAI $61.78
- PMN N/A
- Revenue Next Year
- MDAI N/A
- PMN N/A
- P/E Ratio
- MDAI N/A
- PMN N/A
- Revenue Growth
- MDAI 44.52
- PMN N/A
- 52 Week Low
- MDAI $0.82
- PMN $0.87
- 52 Week High
- MDAI $3.72
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- MDAI 47.72
- PMN 47.06
- Support Level
- MDAI $1.95
- PMN $0.89
- Resistance Level
- MDAI $2.24
- PMN $1.02
- Average True Range (ATR)
- MDAI 0.30
- PMN 0.08
- MACD
- MDAI -0.07
- PMN -0.01
- Stochastic Oscillator
- MDAI 11.54
- PMN 21.36
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.